Kevin Kotler is bullish on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and has decided to boost his fund’s investment in the stock. Kotler’s Broadfin Capital has increased its holding by 60% to a little over 8.95 million shares, as reported in a recent filing with the Securities and Exchange Commission. The fund’s current ownership of the stock gives it control over 12.9% of the total number of shares outstanding.
Julian and Felix Baker also like Progenics Pharmaceuticals, Inc. and have increased their investment during the first quarter of 2014. As reported in its latest 13F filing, Baker Bros. Advisors holds approximately 4.45 million shares, up 6% from the end of 2013. Paul Tudor Jones is not so optimistic, though, and has chosen to trim his fund’s stake in the company by 1% during the same period of time. Tudor Investment Corp reportedly holds 2.34 million shares of Progenics Pharmaceuticals, Inc.. James Dondero is of the same opinion and has reduced his fund’s investment by 6% to a little over 1.38 million shares.
Discosure: none.
